Genmab and AbbVie announced on October 5, 2026, positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab, a subcutaneously administered T-cell engaging bispecific antibody, in combination with standard of care R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone) versus R-CHOP alone in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and […]
Roche announced on September 17, 2026, that the phase III CELESTIMO study evaluating mosunetuzumab (Lunsumio) in combination with lenalidomide met its primary endpoint in people with relapsed or refractory follicular lymphoma (FL) who had received at least one prior line of treatment. The comparator arm was rituximab (MabThera/Rituxan) plus lenalidomide. At the interim analysis, the […]
The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for mosunetuzumab (Lunsumio VELO) in combination with polatuzumab vedotin (Polivy) for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), who have received at least one prior systemic therapy. The […]
New Phase 3 frontMIND data to be presented at ASCO 2026 spotlight tafasitamab plus lenalidomide and R-CHOP in newly diagnosed high-risk DLBCL. The pivotal trial evaluates a frontline CD19-targeted immunotherapy strategy, with Incyte indicating the findings support future regulatory submissions.
Sonrotoclax (BGB-11417; Beqalzi) is a next-generation, highly selective B-cell lymphoma 2 (BCL-2) inhibitor that recently received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 13, 2026, for the treatment of adults with relapsed or refractory mantle cell lymphoma (R/R MCL) after at least two prior lines of systemic therapy, including a […]
Mosunetuzumab showed early promise for improving outcomes in two key lymphoma subtypes with 88% response rates in MCL.
ctDNA detection after LBCL therapy predicts 97% vs 29% progression-free survival, superior to PET scans for determining true remission status.
40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60, P=.0017) – POLARGO trial results.